Tag
A 9-year-old girl with atopic dermatitis and relapsing nephrotic syndrome achieved sustained remission of both conditions after dupilumab therapy, enabling withdrawal of steroids and tacrolimus.
In a phase 2 trial, oral QY201 significantly improved skin outcomes in moderate-to-severe atopic dermatitis with favorable safety, supporting further phase 3 evaluation.
This analysis of the 4-year PEDISTAD registry reveals dupilumab’s superior effectiveness and comparable safety in treating moderate-to-severe atopic dermatitis in children across diverse racial groups.
This study reveals that 30.7% of atopic dermatitis patients treated with dupilumab develop ocular surface disease, despite prevalent ocular symptoms at baseline and increased ophthalmic treatment during therapy, linked to reduced conjunctiv
A randomized clinical trial shows online team-based care is as effective as conventional in-person treatment for atopic dermatitis, offering an accessible alternative for chronic disease management.
Emerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.
Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.
This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d
A large meta-analysis found JAK-STAT inhibitors slightly increased influenza, bronchitis, and herpes zoster risk, especially in atopic dermatitis, while serious and opportunistic infections were not significantly increased.
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
A pragmatic RCT comparing weekly versus daily bathing in 438 eczema patients found no significant difference in symptom severity, supporting patient autonomy in choosing hygiene routines.
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient
This comprehensive systematic review and meta-analysis of 190 studies involving 2.8 million participants establishes a 4.7% incidence rate for childhood food allergy and identifies early atopic conditions, microbiome disruptions, and delaye
This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.
Recent findings from the COPSAC2010 trial and EDEN cohort suggest that high-dose prenatal vitamin D’s protective effect against atopic dermatitis is significantly enhanced in children of mothers exposed to tobacco, highlighting a pote
